Enliven Therapeutics, Inc. · NASDAQ:ELVN
Hohl Benjamin sold 6,018 Enliven Therapeutics, Inc. shares (Form 4)
Traded Sep 17, 2026 · Filed Sep 21, 2026
On Sep 17, 2026, Hohl Benjamin (CHIEF FINANCIAL OFFICER) sold 6,018 Enliven Therapeutics, Inc. shares at an average US$50.35 for US$303K under a trading plan, leaving 38,000 shares. Filed Sep 21, 2026 (Form 4).
- Sold
- 6,018 shares
- Price
- US$50.35 average (US$50.03 to US$51.49)
- Value
- US$303K
- Holding after
- 38,000 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- CHIEF FINANCIAL OFFICER
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | Common Stock | Option exercise | 3,982 | US$14.85 | 44,018 | Direct |
| Sep 17, 2026 | Common Stock | Sale | 3,535 | US$50.03 | 40,483 | Direct |
| Sep 17, 2026 | Common Stock | Sale | 2,194 | US$50.72 | 38,289 | Direct |
| Sep 17, 2026 | Common Stock | Sale | 289 | US$51.49 | 38,000 | Direct |
Source
Related
- Enliven Therapeutics, Inc.
- Hohl Benjamin
- Enliven Therapeutics, Inc. shareholders
- Form 4 · Hohl Benjamin · Aug 19, 2026
- Form 4 · Hohl Benjamin · Jul 21, 2026
- Form 4 · Hohl Benjamin · Jun 22, 2026
- Form 4 · Garland J. Scott · Oct 5, 2026
- Form 4 · Collins Helen Louise · Sep 21, 2026
- Form 4 · Collins Helen Louise · Aug 19, 2026
- Form 4 · Derynck Mika K · Aug 6, 2026
- Schedule 13G/A · FMR LLC · Aug 6, 2026